KR20120122664A - Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract - Google Patents
Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract Download PDFInfo
- Publication number
- KR20120122664A KR20120122664A KR1020110040964A KR20110040964A KR20120122664A KR 20120122664 A KR20120122664 A KR 20120122664A KR 1020110040964 A KR1020110040964 A KR 1020110040964A KR 20110040964 A KR20110040964 A KR 20110040964A KR 20120122664 A KR20120122664 A KR 20120122664A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- myeongil
- composition
- water
- obesity
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 174
- 208000008589 Obesity Diseases 0.000 title claims abstract description 35
- 235000020824 obesity Nutrition 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 241001105098 Angelica keiskei Species 0.000 title abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 8
- 235000009852 Cucurbita pepo Nutrition 0.000 claims description 6
- 235000004347 Perilla Nutrition 0.000 claims description 5
- 244000124853 Perilla frutescens Species 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 239000012223 aqueous fraction Substances 0.000 claims description 2
- 241000219122 Cucurbita Species 0.000 claims 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 30
- 239000004480 active ingredient Substances 0.000 abstract description 12
- 210000000577 adipose tissue Anatomy 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 6
- 201000010063 epididymitis Diseases 0.000 abstract description 5
- 230000037396 body weight Effects 0.000 abstract description 3
- 210000000918 epididymis Anatomy 0.000 abstract 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003158 alcohol group Chemical group 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 18
- 238000000926 separation method Methods 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 12
- 235000009200 high fat diet Nutrition 0.000 description 11
- 239000006227 byproduct Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003579 anti-obesity Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 240000001980 Cucurbita pepo Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000005549 size reduction Methods 0.000 description 4
- 229920002472 Starch Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- -1 n-nucleic acid Chemical compound 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 명일엽 추출물을 포함하는 비만 예방 및 치료용 조성물에 관한 것으로, 보다 상세하게는 명일엽 녹즙의 착즙 후, 잔여물인 명일엽박으로부터 수용성 성분을 제거한 명일엽박 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of obesity, including the extract of Mt. It relates to a composition for.
에너지 섭취와 불균형에 의해 발생하는 비만은 유전적인 요인, 고지방 위주의 식습관, 운동 부족, 흡연, 과음 등을 포함하는 환경적인 요인, 스트레스에 의한 심리적인 요인 등 다양한 원인에 의해 유발되는 것으로 알려져 있다. 최근 고지방, 고탄수화물 섭취 증가로 인한 열량 과다섭취와 운동량 부족 등으로 비만 인구가 급증하고 있는 추세이며, 특히 성인뿐만 아니라 소아비만의 유병률이 증가함으로 인해 사회적인 문제로 대두되고 있는 실정이다. 또한 비만은 그 자체가 갖는 문제점뿐만 아니라, 고인슐린혈증, 동맥경화증, 심장 혈관 질환 등과 같은 많은 질병의 원인으로도 작용할 수 있기 때문에 전 세계적으로 비만치료에 많은 관심이 모아지고 있다(Nature, 404: 635-643, 2000; JAMA, 282: 1523-1529, 1999). 현재까지 알려진 비만치료제들 중에서 가장 대표적인 약물들로는 리덕틸 (ReductilTM, 애보트사, 미국), 제니칼(XenicalTM, 로슈제약회사, 스위스), 엑소리제(ExoliseTM, 아토파마, 프랑스) 등이 있으나 심장질환, 호흡기 질환, 신경계질환 등의 심각한 부작용을 일으키는 것으로 보고되고 있다. 현재 비만치료제 개발을 위해 다양한 연구가 이루어지고 있으며, 크게 식욕 억제, 열량흡수의 억제, 발열반응 촉진, 에너지 대사 조절, 미토콘드리아 생합성을 통한 기초대사량 증진 등의 접근법으로 연구가 활발히 이루어 지고 있다 (Nature 404, 635-643, 2000). 이러한 다양한 접근에 대하여 복합적 기능을 나타내는 신규 소재 및 약물을 탐색하고자 하는 시도는 꾸준히 이어져오고 있으나, 현재까지 안전성과 복합적 효능을 동시에 갖고 있는 약물의 개발은 미비한 실정이다. 따라서 천연물로부터 비만 치료 전략에 부합하는 성분을 찾아 약물로써 이용하려는 시도는 합성제제로부터 치료제를 개발하는 것에 비해 식품으로 섭취하여 안전성이 입증된 소재를 활용한다는 측면에서 효율적인 접근방법이라 할 수 있을 것이다.
Obesity caused by energy intake and imbalance is known to be caused by various causes, including genetic factors, high-fat-oriented eating habits, environmental factors including lack of exercise, smoking and heavy drinking, and psychological factors caused by stress. Recently, the obesity population is rapidly increasing due to excessive calorie intake and lack of exercise due to high fat and high carbohydrate intake, and it is a social problem due to the increasing prevalence of childhood obesity as well as adults. Obesity is not only a problem in itself, but also a cause of many diseases such as hyperinsulinemia, arteriosclerosis, and cardiovascular disease, and thus, much attention has been drawn to obesity treatment worldwide (Nature, 404: 635-643, 2000; JAMA, 282: 1523-1529, 1999). Among the most known obesity treatments to date, Reductil TM (Abbott, USA), Xenical TM (Roche Pharmaceuticals, Switzerland), Exolise TM (Atopama, France), etc. It has been reported to cause serious side effects such as respiratory diseases and nervous system diseases. Various studies are currently being conducted to develop obesity treatments, and research is being actively conducted with approaches such as suppressing appetite, suppressing caloric absorption, promoting exothermic reactions, regulating energy metabolism, and enhancing basic metabolism through mitochondrial biosynthesis (Nature 404 , 635-643, 2000). Attempts have been made to search for new materials and drugs exhibiting multiple functions for these various approaches, but until now, the development of drugs having both safety and complex efficacy has been insufficient. Therefore, the attempt to find a component that matches the obesity treatment strategy from natural products and use it as a drug would be an efficient approach in terms of utilizing materials that have been proven safe and consumed as food, compared to developing therapeutic agents from synthetic agents.
최근에는 천연물 유래 신규 기능성 항비만 소재의 탐색에 대한 연구 및 식품 이용이 활발히 이루어지고 있으며, 이 중 국내 웰빙 열풍과 함께 항산화, 항비만, 지질 강하 등의 다양한 생리활성물질을 다량 함유한 녹즙에 대한 관심이 증가하고 있는 추세이다. 현재 국내에는 명일엽, 돌미나리, 당근 등 다양한 과채류를 활용한 녹즙 제품들이 판매되고 있으며, 녹즙 생산량 증가와 함께 녹즙 제조 시 발생하는 착즙 부산물의 발생량도 함께 증가하고 있는 추세이다. 이러한 부산물은 현재 사료로 활용되거나 폐기되고 있는 실정이므로 부산물의 이용에 대한 필요성이 증대되고 있는 실정이다.Recently, research on the search for new functional anti-obesity materials derived from natural products and active use of foods have been actively conducted, among them, green juice containing a large amount of various bioactive substances such as antioxidant, anti-obesity, and lipid lowering along with the domestic well-being hot air. Interest is on the rise. Currently, green juice products using various fruits and vegetables such as Myeongil Leaf, Parsley, Carrot, etc. are being sold, and the production of juice by-products generated during the manufacture of green juice is increasing along with the production of green juice. Since these by-products are currently being used or disposed of as feed, the necessity for using the by-products is increasing.
이에, 본 발명자들은 우수한 항비만 활성을 가지며 안전하게 적용될 수 있는 천연물질을 탐색하는 연구를 수행하던 중, 미나리과 식물인 명일엽(Angelica Keiskei Koid.)의 녹즙 착즙 후 발생하는 부산물인 명일엽 박을 이용하여, 이로부터 수용성 성분을 제거하는 정제 공법을 적용하여 명일엽박 추출물을 제조하고, 상기 추출물이 우수한 체중 감소 효과, 체지방 감소 및 지방세포 크기 감소 효과를 확인하여 본 발명을 완성하였다.
Accordingly, the present inventors, while conducting research to search for natural substances that have excellent anti-obesity activity and can be safely applied, by using Myeong-Il-Pak, which is a by-product generated after the juice of green juice of Angelica Keiskei Koid. From this, the extract was prepared by applying a purification method to remove the water-soluble component, and the extract was confirmed to excellent weight loss effect, body fat reduction and fat cell size reduction effect was completed the present invention.
따라서, 본 발명의 목적은 명일엽 녹즙의 부산물로부터 추출한 명일엽박 추출물을 포함하는 비만 예방 및 치료용 조성물을 제공하는 것이다. Accordingly, it is an object of the present invention to provide a composition for preventing and treating obesity, including the extract of Mt.
상기와 같은 본 발명의 목적을 달성하기 위하여 본 발명은 명일엽박 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 식품 조성물을 제공한다. In order to achieve the object of the present invention as described above, the present invention provides a food composition for the prevention and treatment of obesity comprising the extract of Mt.
본 발명의 다른 목적을 달성하기 위하여, 본 발명은 명일엽박 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물을 제공한다.In order to achieve another object of the present invention, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity, including the extract of Mt.
본 발명의 또다른 목적을 달성하기 위하여, 본 발명은 In order to achieve another object of the present invention, the present invention
(a) 명일엽 박의 유기용매 추출물을 제조하는 단계; (a) preparing an organic solvent extract of perilla leaf gourd;
(b) 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계; 및(b) removing water-soluble components by adding water to the extract of step (a); And
(c) 상기 (b) 단계의 수용성 성분이 제거된 추출물을 탄소수 1 내지 6의 알코올을 첨가하여 알코올 용해 분획을 수득하는 단계를 포함하는 방법에 의해 제조된 비만 예방 및 치료활성을 가지는 명일엽박의 비수용성 분획물을 제공한다.
(c) adding an alcohol having 1 to 6 carbon atoms to the extract from which the water-soluble component of step (b) is removed to obtain an alcohol soluble fraction. Provide a water-insoluble fraction.
이하, 본 발명을 상세히 검토한다.
The present invention is described in detail below.
본 발명의 조성물은 명일엽박의 추출물을 유효성분으로 포함하며, 비만에 대해서 우수한 예방 및 치료 효과를 가지고 있다.
The composition of the present invention includes the extract of Myeongil Leaf Park as an active ingredient, has an excellent preventive and therapeutic effect against obesity.
본 발명에서 명일엽박은 명일엽의 착즙 과정에서 나오는 부산물을 말한다. 착즙은 고체성 혹은 반유동성 원료로부터 액즙을 분리하는 과정으로 예를 들어 대상물을 파쇄 후 압착기로 압착 착즙하는 것을 말한다. 명일엽박은 착즙후 잔류 고형성분을 나타낸다.
In the present invention, Myeongil leaf is the by-product from the juice of Myeongil leaf. The juice is a process of separating the juice from the solid or semi-flowable raw material, for example, crushing the object and then squeezed with a compress. Light leaf leaves show residual solids after juice.
본 발명의 명일엽박 추출물은 바람직하게는 명일엽박의 유기용매 추출물로 이의 비수용성 분획이다.
Myeongil leaf extract of the present invention is preferably an organic solvent extract of Myeongil leaf is its water-insoluble fraction.
바람직하게는 본 발명의 명일엽박 추출물은 Preferably Myeongil leaf extract of the present invention
(a) 명일엽 박의 유기용매 추출물을 제조하는 단계; 및(a) preparing an organic solvent extract of perilla leaf gourd; And
(b) 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계를 포함하는 방법에 의해 제조될 수 있다.
(b) It may be prepared by a method comprising the step of removing water-soluble components by adding water to the extract of step (a).
이를 각 단계별로 상세히 설명하면 다음과 같다.
The detailed description of each step is as follows.
(a)단계는 명일엽 박의 유기용매 추출물을 제조하는 단계이다.
Step (a) is a step of preparing an organic solvent extract of Myeongil Leaf Park.
본 단계에서 명일엽박은 당업계에 공지된 용매 추출법에 의해 추출될 수 있다. 추출 용매로는 이에 제한되지는 않으나, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 펜탄올, 헥산올과 같은 탄소수 1 내지 6개의 알코올, 아세톤, 에틸아세테이드, n-핵산, 디에틸에테르, 아세톤, 벤젠과 같은 유기용매 중에서 선택된 어느 하나 또는 이들의 혼합용매를 사용할 수 있다. 바람직하게는 탄소수 1개 내지 6개의 알코올 또는 이의 혼합용매로 추출할 수 있으며, 더욱 바람직하게는 에탄올을 용매로 추출할 수 있다.
In this step, the day leaf can be extracted by a solvent extraction method known in the art. Extraction solvents include, but are not limited to, alcohols having 1 to 6 carbon atoms, such as methanol, ethanol, propanol, isopropanol, butanol, pentanol, hexanol, acetone, ethyl acetate, n-nucleic acid, diethyl ether, acetone , Any one selected from organic solvents such as benzene, or a mixed solvent thereof may be used. Preferably it can be extracted with an alcohol having 1 to 6 carbon atoms or a mixed solvent thereof, more preferably ethanol can be extracted with a solvent.
본 발명의 일실시예에서는 에탄올을 용매로 이용하여 추출하였으며, 그 수율을 향상시키기 위하여 100% 에탄올을 용매로 이용하였다. 추출 시간은 이에 제한되지는 않으나, 1 내지 20시간동안 추출할 수 있으며, 바람직하게는 10 내지 15시간동안 추출하며, 더욱 바람직하게는 12 내지 13시간동안 추출할 수 있다. 또한, 추출 온도는 이에 제한되지는 않으나, 25℃ 내지 75℃에서 추출할 수 있고, 보다 바람직하게는 50 내지 60℃에서 추출할 수 있으나, 75℃ 초과에서는 안정도가 떨어져 추출 공정의 수행이 어려워 바람직하기 않으며, 25℃ 미만에서는 추출효율이 떨어져 바람직하지 않다.
In one embodiment of the present invention was extracted using ethanol as a solvent, in order to improve the yield 100% ethanol was used as the solvent. Extraction time is not limited thereto, but may be extracted for 1 to 20 hours, preferably for 10 to 15 hours, more preferably for 12 to 13 hours. In addition, the extraction temperature is not limited to this, but may be extracted at 25 ℃ to 75 ℃, more preferably 50 to 60 ℃ can be extracted, but above 75 ℃ the stability is difficult to perform the extraction process is preferred In this case, the extraction efficiency is lower than 25 ° C., which is not preferable.
(b)단계는 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계이다.
Step (b) is a step of removing water-soluble components by adding water to the extract of step (a).
본 단계에서는 수용성 성분을 제거하여 비수용성 침전물을 수득하기 위한 단계이다. 수용성 성분을 제거하기 위한 방법은 당업계에서 공지된 방법에 의할 수 있으며, 예를 들어, 과량의 물을 첨가하고, 교반하여 수용성 성분이 물에 녹도록 하여 제거할 수 있다. 또한 물을 첨가하고 이의 정제과정에서 수용성 성분을 제거, 즉 이에 제한되지는 않으나, 여과지를 이용한 분리, 한외여과막을 이용한 분리 및 크로마토그래피에 의한 분리, 탈색 과정 중에 제거할 수 있다. 또한, 치소필터로 여과하여 침전물을 수득하고, 이를 다시 물과 혼합하여 다시 여과하는 방법에 따라 수행될 수 있다.
In this step, the water-soluble component is removed to obtain a water-insoluble precipitate. The method for removing the water soluble component may be by a method known in the art, for example, by adding an excess of water and stirring to remove the water soluble component in water. In addition, water may be added and the water-soluble component may be removed during the purification thereof, that is, the present invention is not limited thereto, but may be removed during separation using a filter paper, separation using an ultrafiltration membrane, separation by chromatography, and decolorization. In addition, it can be carried out according to the method of filtration with a Chiso filter to obtain a precipitate, which is mixed with water again and filtered again.
본 발명의 명일엽박 추출물은 (c) 상기 (b) 단계의 수용성 성분이 제거된 추출물을 탄소수 1 내지 6의 알코올을 첨가하여 알코올 용해 분획을 수득하는 단계를 추가로 포함하는 방법에 의해 제조될 수 있다.Myeongil leaf extract of the present invention may be prepared by a method further comprising the step of (c) 추출물 to obtain an alcohol dissolution fraction by adding an alcohol having 1 to 6 carbon atoms to the extract from which the water-soluble component of step (b) is removed. have.
즉, 본 발명의 명일엽박 추출물은 In other words, Myeongil foliar extract of the present invention
(a) 명일엽 박의 유기용매 추출물을 제조하는 단계; (a) preparing an organic solvent extract of perilla leaf gourd;
(b) 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계; 및(b) removing water-soluble components by adding water to the extract of step (a); And
(c) 상기 (b) 단계의 수용성 성분이 제거된 추출물을 탄소수 1 내지 6의 알코올을 첨가하여 알코올 용해 분획을 수득하는 단계를 포함하는 방법에 의해 제조될 수 있다.
(c) The extract from which the water-soluble component of step (b) is removed may be prepared by a method comprising adding an alcohol having 1 to 6 carbon atoms to obtain an alcohol soluble fraction.
상기 (a), (b) 단계는 상기 기재한 바와 같으며, (c) 단계는 상기 (b) 단계의 수용성 성분이 제거된 추출물을 탄소수 1 내지 6의 알코올을 첨가하여 알코올 용해 분획을 수득하는 단계이다.
Steps (a) and (b) are as described above, and step (c) is performed by adding an alcohol having 1 to 6 carbon atoms to the extract from which the water-soluble component of step (b) is removed to obtain an alcohol soluble fraction. Step.
알코올의 첨가로 본 발명의 유효성분의 함량이 높아지며, 다른 비활성성분을 추가적으로 제거할 수 있는 효과가 있다. 알코올은 바람직하게는 탄소수 1 내지 6의 알코올, 더 바람직하게는 메탄올, 에탄올, 프로판올, 부탄올, 펜탄올, 헥산올, 가장 바람직하게는 에탄올을 이용할 수 있다. 알코올에는 흡습성 등 물리화학적 성질을 반영하기 위하여 소량의 물(예를 들어, 95% 에탄올, 99% 에탄올의 형태)이 첨가된 형태일 수도 있다. 처리온도 및 시간은 비활성성분의 제거의 목적이 달성되는 한 특별히 제한되지는 않으나, 30 내지 50℃에서 30분 내지 12시간동안 처리할 수 있다.
The addition of alcohol increases the content of the active ingredient of the present invention, there is an effect that can additionally remove other inactive ingredients. The alcohol is preferably an alcohol having 1 to 6 carbon atoms, more preferably methanol, ethanol, propanol, butanol, pentanol, hexanol, and most preferably ethanol. The alcohol may be in a form in which a small amount of water (eg, 95% ethanol, 99% ethanol) is added to reflect physicochemical properties such as hygroscopicity. The treatment temperature and time are not particularly limited as long as the purpose of removing the inactive components is achieved, but may be treated at 30 to 50 ° C. for 30 minutes to 12 hours.
아울러, 상기 (b) 단계의 수용성 물질의 제거 및 (c) 단계의 알코올의 추가 처리로 본 발명의 명일엽박 추출물의 관능이 개선되어 이의 활용성이 높아지는 효과가 있다.
In addition, by removing the water-soluble substance of the step (b) and the additional treatment of the alcohol of the step (c) of the extract of the Myeongil leaf extract of the present invention has the effect of increasing its utility.
한편, 본 발명의 명일엽박 추출물의 제조시 처리, 보관 등의 용이함을 위하여 농축 및 정제과정, 여과 과정, 건조과정, 동결과정, 분말화 과정이 임의로 추가될 수 있다.
On the other hand, the concentration and purification process, filtration process, drying process, freezing process, powdering process may be optionally added for ease of treatment, storage and the like during the preparation of the extract of Myeongil foliar extract of the present invention.
농축 과정은 이에 제한되지는 않으나, 침전농축, 증발농축, 감압농축, 한외여과법, 역삼투법 및 원심분리법을 이용하여 농축할 수 있으며, 여과 과정은 이에 제한되지는 않으나 여과망 또는 마이크로필터를 이용한 여과, 원심분리 및 분액 깔때기를 이용할 수 있다. 건조 과정은 이에 제한되지는 않으나, 동결 건조 또는 분무 건조일 수 있고, 덱스트린 포접 등의 과정에 의해 분말화될 수 있다.
The concentration process is not limited thereto, but may be concentrated using precipitation concentration, evaporation concentration, reduced pressure concentration, ultrafiltration, reverse osmosis, and centrifugal separation, and the filtration process is not limited thereto. Separation and separation funnels may be used. The drying process is not limited thereto, but may be freeze drying or spray drying, and may be powdered by a process such as dextrin inclusion.
본 발명의 일실시예에서는 명일엽박의 추출을 위하여 유효 조건들을 확립하고, 본 발명의 다른 실시예에서는 이를 바탕으로 하여 명일엽박 추출물, 보다 구체적으로는 명일엽박의 에탄올 추출물의 비수용성 분획을 제조하였다.
In one embodiment of the present invention to establish the effective conditions for the extraction of Myeongil leaf, in another embodiment of the present invention on the basis of this to prepare a non-aqueous fraction of Myeongil leaf extract, more specifically ethanol extract of .
본 발명의 실험예에서는 상기에서 제조된 명일엽박 추출물을 비만모델 마우스에 투여하여 비만의 예방 및 치료효과를 확인하였다. 그 결과, 비투여 대조군 및 명일엽 착즙액 투여 대조군에 비해서 우수한 비만 예방/치료 효과가 있음을 확인할 수 있었다(도 1). 아울러, 우수한 체지방 감소 효과를 보였으며(도 2), 지방세포의 크기도 감소됨을 확인할 수 있었다(도 3).
In the experimental example of the present invention, the extract of Myeongil foliar extract prepared above was administered to an obese model mouse to confirm the prevention and treatment of obesity. As a result, it was confirmed that there is an excellent obesity prevention / treatment effect as compared to the non-administered control group and daylight juice administration control group (Fig. 1). In addition, it showed an excellent body fat reduction effect (Fig. 2), it was confirmed that the size of fat cells is also reduced (Fig. 3).
본 발명의 조성물은 우수한 비만 예방 및 치료효과를 가진다. 따라서, 본 발명은 명일엽박 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 식품 조성물을 제공한다.
The composition of the present invention has an excellent obesity prevention and treatment effect. Therefore, the present invention provides a food composition for the prevention and treatment of obesity, including the extract of Mt.
상기 본 발명의 식품 조성물은 기능성 식품(functional food), 영양보조제(nutritional supplement), 건강식품(health food) 및 식품 첨가제(food additives) 등의 모든 형태를 포함한다.
The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives.
상기 유형의 식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 이에 한정되지 않지만 예를 들면, 건강식품으로는 명일엽박 추출물을 차, 쥬스 및 드링크의 형태로 제조하여 음용할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 명일엽박 추출물과 비만에 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다. 또한, 기능성 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게티, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예:버터, 치즈 등), 식용식물유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 명일엽박 추출물을 첨가하여 제조할 수 있다. 또한, 명일엽 추출물을 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다.
Food compositions of this type can be prepared in various forms according to conventional methods known in the art. For example, but not limited to, health food can be consumed by liquefaction, granulation, encapsulation and powdered so that the extract of Myeongil foliar extract in the form of tea, juice and drinks to drink. In addition, it can be prepared in the form of a composition by mixing with Myeongil leaf extract and known active ingredients known to have an effect on obesity. In addition, functional foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned food, jams, marmalade, etc.), fish, meat and processed foods (e.g. ham) , Sausage cornbeans, etc., breads and noodles (e.g. udon, soba noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, candy, dairy products (e.g. butter, cheese, etc.), edible vegetable oils, margarine , Vegetable protein, retort foods, frozen foods, various seasonings (eg, miso, soy sauce, sauce, etc.) may be prepared by adding Myeongil leaf extract. In addition, in order to use the extract of the day single leaf in the form of food additives can be prepared in the form of powder or concentrate.
본 발명의 식품 조성물 중 명일엽박 추출물의 바람직한 함유량으로는 이에 한정되지 않지만 바람직하게는 최종적으로 제조된 식품 중 0.1 내지 90 중량%이다. 더 바람직하게는, 본 발명의 명일엽박 추출물을 유효성분으로 함유하는 식품 조성물은 특히, 비만에 효과가 있는 것으로 알려진 활성 성분과 함께 혼합하여 건강식품의 형태로 제조될 수 있다.
Preferable content of the extract of Mt. Foliage in the food composition of the present invention is not limited thereto, but is preferably 0.1 to 90% by weight of the finally prepared food. More preferably, the food composition containing the extract of Myeong il bak leaf of the present invention as an active ingredient may be prepared in the form of health food, especially by mixing with active ingredients known to be effective in obesity.
아울러, 본 발명은 명일엽박 추출물을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물을 제공한다.
In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity, including the extract of Mt.
상기 약학적 조성물의 경우에는 상기 명일엽박 추출물을 단독으로 포함하거나 또는 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 상기에서 '약학적으로 허용되는'이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다.
In the case of the pharmaceutical composition may include the extract of Sunil leaf alone or may further include one or more pharmaceutically acceptable carriers, excipients or diluents. As used herein, 'pharmaceutically acceptable' refers to a composition that is physiologically acceptable and does not normally cause an allergic or similar reaction when administered to a human.
약학적으로 허용되는 담체로는 예컨대, 경구 투여용 담체 또는 비경구 투여용 담체를 추가로 포함할 수 있다. 경구 투여용 담체는 락토스, 전분, 셀룰로스 유도체, 마그네슘 스테아레이트, 스테아르산 등을 포함할 수 있다. 또한, 비경구 투여용 담체는 물, 적합한 오일, 식염수, 수성 글루코스 및 글리콜 등을 포함할 수 있으며, 안정화제 및 보존제를 추가로 포함할 수 있다. 적합한 안정화제로는 아황산수소나트륨, 아황산나트륨 또는 아스코르브산과 같은 항산화제가 있다. 적합한 보존제로는 벤즈알코늄 클로라이드, 메틸- 또는 프로필-파라벤 및 클로로부탄올이 있다. 그 밖의 약학적으로 허용되는 담체로는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있다(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).
본 발명의 비만의 예방 또는 치료용 약학적 조성물은 인간을 비롯한 포유동물에 어떠한 방법으로도 투여할 수 있다. 예를 들면, 경구 또는 비경구적으로 투여할 수 있다. 비경구적인 투여방법으로는 이에 한정되지는 않으나, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장내 투여일 수 있다. 바람직하게는 본 발명의 약학적 조성물은 경피 투여될 수 있다. 상기에서 ‘경피 투여'란 본 발명의 약학적 조성물을 세포 또는 피부에 투여하여 비만의 예방 또는 치료용 약학적 조성물에 함유된 활성성분이 피부 내로 전달되도록 하는 것을 말한다. 예컨대, 본 발명의 약학적 조성물을 주사형 제형으로 제조하여 이를 30 게이지의 가는 주사 바늘로 피부를 가볍게 단자(prick)하는 방법, 또는 피부에 직접적으로 도포하는 방법으로 투여될 수 있다.
The pharmaceutical composition for preventing or treating obesity of the present invention can be administered to any mammal, including humans. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration. Can be. Preferably the pharmaceutical composition of the present invention may be administered transdermally. As used herein, 'transdermal administration' refers to the administration of the pharmaceutical composition of the present invention to cells or skin to deliver the active ingredients contained in the pharmaceutical composition for the prevention or treatment of obesity into the skin. For example, the pharmaceutical composition of the present invention can be prepared in an injectable formulation and administered by lightly pricking the skin with a 30 gauge thin needle or by applying it directly to the skin.
또한, 상기 약학적 조성물은 상술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다.
In addition, the pharmaceutical composition may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.
경구 투여용 제제의 경우에 본 발명의 조성물은 분말, 과립, 정제, 환제, 당의정제, 캡슐제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 등으로 당업계에 공지된 방법을 이용하여 제형화될 수 있다. 예를 들어, 경구용 제제는 활성 성분을 고체 부형제와 배합한 다음 이를 분쇄하고 적합한 보조제를 첨가한 후 과립 혼합물로 가공함으로써 정제 또는 당의정제를 수득할 수 있다. 적합한 부형제의 예로는 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨 및 말티톨 등을 포함하는 당류와 옥수수 전분, 밀 전분, 쌀 전분 및 감자 전분 등을 포함하는 전분류, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸-셀룰로즈 등을 포함하는 셀룰로즈류, 젤라틴, 폴리비닐피롤리돈 등과 같은 충전제가 포함될 수 있다. 또한, 경우에 따라 가교결합 폴리비닐피롤리돈, 한천, 알긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있다. 나아가, 본 발명의 약학적 조성물은 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.
In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and the like. Can be. For example, oral formulations can obtain tablets or dragees by combining the active ingredients with solid excipients and then grinding them, adding suitable auxiliaries and processing them into granule mixtures. Examples of suitable excipients include, but are not limited to, sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.
비경구 투여용 제제의 경우에는 주사제, 크림제, 로션제, 외용연고제, 오일제, 보습제, 겔제, 에어로졸 및 비강 흡입제의 형태로 당업계에 공지된 방법으로 제형화할 수 있다. 이들 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour)에 기재되어 있다.
Formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known in all pharmaceutical chemistries.
본 발명의 명일엽박 추출물의 총 유효량은 단일 투여량(single dose)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple dose)으로 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 본 발명의 약학적 조성물은 질환의 정도에 따라 유효성분의 함량을 달리할 수 있다. 바람직하게 본 발명의 명일엽박 추출물의 바람직한 전체 용량은 1일당 환자 체중 1 ㎏ 당 약 0.01 ㎍ 내지 1,000 mg, 가장 바람직하게는 0.1 ㎍ 내지 100 mg일 수 있다. 그러나 상기 명일엽박 추출물의 용량은 약학적 조성물의 투여 경로 및 치료 횟수뿐만 아니라 환자의 연령, 체중, 건강 상태, 성별, 질환의 중증도, 식이 및 배설율등 다양한 요인들을 고려하여 환자에 대한 유효 투여량이 결정되는 것이므로, 이러한 점을 고려할 때 당 분야의 통상적인 지식을 가진 자라면 상기 명일엽박 추출물의 비만의 예방 또는 치료제로서의 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다. 본 발명에 따른 약학적 조성물은 본 발명의 효과를 보이는 한 그 제형, 투여 경로 및 투여 방법에 특별히 제한되지 아니한다.
The total effective amount of the extract of the day leaf extract of the present invention may be administered to a patient in a single dose, and may be administered by a fractionated treatment protocol administered for a long time in multiple doses. . The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease. Preferably the preferred total dose of the extract of Myeongil Foil is from about 0.01 μg to 1,000 mg, most preferably 0.1 μg to 100 mg per kg of patient body weight per day. However, the dose of the extract of Myeongil leaf extract is effective dose to the patient in consideration of various factors such as the age, weight, health condition, sex, severity of the disease, diet and excretion rate, as well as the route and frequency of treatment of the pharmaceutical composition In this regard, one of ordinary skill in the art will be able to determine an appropriate effective dosage for the specific use as a prophylactic or therapeutic agent for obesity. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.
나아가, 상기 약학 조성물은 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.
Furthermore, the pharmaceutical composition may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.
비경구 투여용 제제의 경우에는 주사제의 형태로 당업계에 공지된 방법으로 제형화 할 수 있다. 이들 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour)에 기재 되어 있다.Formulations for parenteral administration may be formulated in the form of injections by methods known in the art. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known in all pharmaceutical chemistries.
이상 살펴본 바와 같이, 본 발명의 명일엽박 추출물은 원물인 명일엽의 착즙액에 비해서도 우수한 체중감소, 체지방 감소 및 지방세포의 크기 감소 효과를 가진다. 따라서, 본 발명의 명일엽박 추출물은 비만 예방 및 치료의 목적으로 유용하게 이용될 수 있다.As described above, the Myeongil leaf extract of the present invention has an excellent weight loss, body fat reduction and fat cell size reduction effect compared to the juice of the original Myeongil leaf. Therefore, Myeongil leaf extract of the present invention can be usefully used for the purpose of preventing and treating obesity.
도 1은 정상군(이하 ‘Normal’로 표시), 고지방 식이 대조군(이하 ‘Control’로 표시), 명일엽 착즙액 투여군(이하 ‘명일엽 착즙액’으로 표시), 명일엽박 추출물 투여군(이하 ‘명일엽박 추출물’로 표시) 투여에 따른 체중 변화를 측정한 결과를 나타낸 것이다.
도 2는 고지방 식이로 유도된 비만마우스에서 명일엽박 추출물 투여에 의한 체지방 함량의 변화를 측정한 결과를 나타낸 것이다.
도 3은 고지방 식이로 유도된 비만마우스에서 명일엽박 추출물 투여 시 지방세포 크기의 변화를 측정한 결과를 나타낸 것이다. 1 is a normal group (hereinafter referred to as 'Normal'), a high fat diet control group (hereinafter referred to as 'Control'), Myeongil leaf juice administration group (hereinafter referred to as 'day leaf juice'), Myeongil leaf extract administration group (hereinafter 'Myeongil leaf leaf' It shows the result of measuring the weight change according to the administration).
Figure 2 shows the results of measuring the change in the body fat content by administration of the extract from the leaves of obesity in obese mice induced by high fat diet.
Figure 3 shows the results of measuring the change in fat cell size when administered Myeongil leaf extract in obese mice induced by high fat diet.
이하, 본 발명을 실시예에 의해 상세히 설명한다. Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<실시예 1>≪ Example 1 >
명일엽박 추출물 제조의 최적 조건 설정Setting Optimum Conditions for Preparation of Mt.
본 발명의 명일엽박 추출물 제조를 위한 최적의 조건을 설정하기 위하여 하기와 같이 실험을 수행하였다. 본 발명에서 명일엽 원료는 명일엽 녹즙을 착즙하고 남은 고형 성분의 부산물(명일엽 박)을 사용하였다.
The experiment was carried out as follows to set the optimum conditions for the preparation of Mt. In the present invention, the raw material of Myeongil leaf was used as a by-product (myeongil leaf gourd) of the remaining solid components of the juice of Myeongil leaf.
1. 추출 용매, 시간 및 온도 1. Extraction solvent, time and temperature
추출용매에 따른 추출효율을 비교하기 위하여 정제수, 30% 에탄올, 60% 에탄올 및 100% 에탄올로 80℃에서 3시간 추출하였으며, 그 결과 정제수로 추출한 경우 에탄올 추출에 비하여 수율 추출 전, 후 건조물량(고형분 함량)을 비교, 계산한 수율이 매우 떨어지는 것을 확인하였다. 에탄올 추출의 경우 100% 에탄올로 추출한 경우 가장 효율이 높은 것으로 나타났다.In order to compare the extraction efficiency according to the extraction solvent, extracted with purified water, 30% ethanol, 60% ethanol and 100% ethanol at 80 ℃ for 3 hours. Solid content content) was compared and the calculated yield was found to be very low. In the case of ethanol extraction, extraction with 100% ethanol showed the highest efficiency.
추출시간에 따른 추출효율을 비교하기 위하여 추출시간을 5시간, 10시간, 15시간 및 20시간으로 하여 추출하였다. 그 결과 10시간과 15시간 사이에서 추출효율이 가장 크게 증가하는 것으로 나타났다. 따라서 10시간에서 15시간까지 1시간 간격으로 추출 시간을 설정하여 비교하였다. 그 결과 12시간에서 13시간 동안 추출하는 경우가 가장 효율이 높은 것으로 나타났다.In order to compare the extraction efficiency according to the extraction time, the extraction time was extracted as 5 hours, 10 hours, 15 hours and 20 hours. As a result, the extraction efficiency increased the most between 10 and 15 hours. Therefore, the extraction time was set at 1 hour interval from 10 hours to 15 hours and compared. As a result, the extraction was the most efficient in the case of extraction for 12 to 13 hours.
추출온도에 따른 추출효율을 비교하기 위하여 추출온도를 실온, 25℃ 및 75℃로 하여 추출하였으며, 그 결과 온도가 높아질수록 고형물의 함량이 증가하기는 하나 75℃ 이상은 안정도가 떨어져 공정 수행이 어려워 50℃ 내지 60℃가 적합한 것으로 나타났다.
In order to compare the extraction efficiency according to the extraction temperature, the extraction temperature was extracted at room temperature, 25 ℃ and 75 ℃. As a result, the solid content increased as the temperature increased, but the process was difficult because the stability was lower than 75 ℃. 50 ° C. to 60 ° C. has been found to be suitable.
2. 농축 및 여과 2. Concentration and Filtration
가장 효율적인 농축 농도를 확립하기 위하여 상기 추출된 추출물을 1/2비율, 1/5비율 및 최대로 비율을 달리하여 농축을 실시하였다. 그 결과 농축율이 높아짐에 따라 고형물의 생성도 함께 증가하기는 하나 최대로 농축하는 경우 회수 시 손실분이 발생하므로 1/5의 비율이 적합한 것으로 확인되었다. In order to establish the most efficient concentration concentration, the extracted extract was concentrated at 1/2 ratio, 1/5 ratio and at maximum ratio. As a result, as the concentration increased, the solids also increased, but the loss of recovery occurred at the maximum concentration.
유효성분 회수를 위한 여과공정을 최적화하기 위하여 20메쉬 여과망 또는 마이크로필터를 이용한 여과, 원심분리 및 분액깔때기를 이용한 여과를 실시하였다. 그 결과 원심분리의 경우 회수 효율은 높으나 회수시 다량의 손실분이 발생하며, 분액깔때기의 경우 분리 시간이 길며 용량이 적고 정밀분리가 어려운 것으로 나타났다. 여과망을 이용한 경우 20메쉬 여과망은 회수율이 적고, 마이크로필터를 이용하는 경우 회수율이 양호하며 작업 효율이 높은 것을 확인하였다.
In order to optimize the filtration process for recovering the active ingredient, filtration using a 20 mesh filter network or a micro filter, filtration using a centrifugation separator and a funnel was performed. As a result, in case of centrifugation, the recovery efficiency is high, but a large amount of loss occurs during recovery, and the separation funnel has a long separation time, a small capacity, and difficult separation. In the case of using the filter network, the 20 mesh filter network has a low recovery rate, and when the micro filter is used, the recovery rate is good and the working efficiency is high.
3. 분리 및 정제3. Separation and Purification
에탄올로 추출한 추출물을 감압농축방법으로 농축하여 불용성 침전물을 회수 건조하여 알콜에 녹이고 여과지로 여과 후 농축 건조하여 비수용성 성분을 수득하고 상기 불용성 침전물을 회수하고 남은 용액을 농축 건조하여 수용성 성분을 수득하는 방법으로 수용성 성분과 비수용성 성분을 분리하였다.The extract extracted with ethanol was concentrated under reduced pressure, and the insoluble precipitate was recovered and dried, dissolved in alcohol, filtered through a filter paper and concentrated to dryness to obtain a water-insoluble component. The water-soluble and water-insoluble components were separated by the method.
추출 용매로는 물, 에탄올 및 메탄올과 같은 탄소수 1 내지 6개의 알코올, 아세톤, 에틸아세테이드, n-핵산, 디에틸에테르, 아세톤, 벤젠과 같은 유기용매 중에서 선택된 어느 하나 또는 이들의 혼합용매를 사용할 수 있다. 상기의 추출물에 대해 당업계에 공지된 농축장치, 농축법을 이용하여 농축하고 농축물에 대해 수용성 성분을 제거하기 위해 여과지를 이용한 침전물 분리, 한외여과막을 이용한 분리, 다양한 크로마토그래피에 의한 분리, 탈색과정 등의 정제공정을 적용하였다. 마지막으로 수용성 성분이 제거된 농축액을 동결건조, 분무건조, 덱스트린 포접 등의 방법에 따라 분말화하였다. 그러나, 유효성분의 추출 및 분리정제 방법은 반드시 상기한 방법에 한정되는 것은 아니다.
The extraction solvent may be any one selected from alcohols having 1 to 6 carbon atoms such as water, ethanol and methanol, organic solvents such as acetone, ethyl acetate, n-nucleic acid, diethyl ether, acetone, benzene, or a mixed solvent thereof. Can be used. The extract is concentrated using a concentrator known in the art, a concentration method, and the precipitate is separated using a filter paper to remove the water-soluble components from the concentrate, separation using an ultrafiltration membrane, separation by various chromatography, decolorization Purification process such as process was applied. Finally, the concentrated solution from which the water-soluble component was removed was powdered by a method such as lyophilization, spray drying, and dextrin inclusion. However, the extraction and separation and purification method of the active ingredient is not necessarily limited to the above method.
<실시예 2><Example 2>
시료의 제조Preparation of sample
<2-1> <2-1> 명일엽Myung-Yeop 착즙액Juice 제조 Produce
명일엽의 착즙액 및 그 부산물의 항비만 효과를 비교하기 위하여, 먼저 하기 방법으로 명일엽으로부터 착즙액을 제조하였다.
In order to compare the anti-obesity effect of the extract of Myeongil-yeop and its by-products, juice was prepared from Myeongil-yeop first by the following method.
명일엽 500g을 압착하여 착즙액을 얻었다. 보관 및 추후의 실험을 위하여 이를 -80℃에서 1일간 동결시킨 후 수증기의 부분압을 낮춤으로써 얼음을 직접 증기로 만드는 승화작용을 통해 건조시켜 동결 건조 분말을 제조하였다.
500g of light days were squeezed to obtain juice. For storage and later experiments, the freeze-dried powder was prepared by freezing at -80 ° C. for 1 day and then drying it by sublimation to directly ice the ice by lowering the partial pressure of water vapor.
<2-2> <2-2> 명일엽박Leaf leaf 추출물의 제조 Preparation of extract
상기 명일엽 착즙 후, 부산물인 명일엽박을 이용하여 상기 실시예 1에서 설정된 조건에 따라, 명일엽박 추출물을 하기 방법으로 제조하였다. 명일엽의 녹즙 착즙 후의 부산물 350g에 300중량%의 에탄올을 투입하여 교반하면서 55℃에서 12시간 동안 추출하였다. 추출액을 이송관을 통하여 이송시키면서 이송관 내에서 1mesh에서 150mesh까지 여과하고, 이를 다시 증발건조기(evaporator)를 이용하여 40브릭스(brix)로 저온 농축하여 에탄올 성분을 제거하고 이를 다시 60브릭스까지 55℃에서 농축하였다.After the extract of Myeongil lobe, according to the conditions set in Example 1 using the by-product Myeongil lobe, Myeongil lobe extract was prepared by the following method. 300 g of ethanol was added to 350 g of the by-product after extracting the juice of the green leaf, followed by extraction at 55 ° C. for 12 hours. Filtering the extract from 1mesh to 150mesh in the conveying tube while transferring the extract through the conveying tube, and then condensing it by 40 brix at low temperature using an evaporator to remove ethanol and then 55 ° C. until 60 brix. Concentrated at.
상기 용액에서 석출된 성분을 치소필터에 85ml/min의 속도로 통과시켜 침전물을 여과, 회수하였다. 회수 침지된 성분을 85℃에서 6시간 탈수 반응을 진행시켜 수분을 제거하였다.The precipitated component was passed through the Chiso filter at a rate of 85 ml / min, and the precipitate was filtered and recovered. The recovered immersed component was dehydrated at 85 ° C. for 6 hours to remove moisture.
회수된 침전물에서 비수용성 성분의 함량을 높이기 위해 침전물의 10배수의 물을 첨가하고 이를 80℃에서 2시간동안 교반하였다. 이를 냉각한 다음 물을 제거하여 수용성 부분을 제거하였다. 추후의 처리를 위해서 동결 건조하였다. In order to increase the content of the non-aqueous component in the recovered precipitate, 10 times of water of the precipitate was added and stirred at 80 ° C. for 2 hours. After cooling, the water was removed to remove the water-soluble portion. Lyophilized for later treatment.
또한, 추출물의 비수용성 성분을 더욱 높이기 위하여 다시 에탄올(95%)을 침전물의 15배수로 첨가한 다음 용액을 40℃에서 1시간동안 교반하였고, 이를 치소필터로 여과하여 명일엽박 추출물을 얻었다.In addition, in order to further increase the water-insoluble component of the extract, ethanol (95%) was further added to 15 times the precipitate, and the solution was stirred at 40 ° C. for 1 hour.
이를 감압 농축 한 후 동결건조 하여 이하의 동물실험에 사용하였다.
It was concentrated under reduced pressure and freeze-dried and used in the following animal experiments.
<< 실험예Experimental Example 1> 1>
명일엽박Leaf leaf
추출물의 체중 감소 효과 Weight loss effect of extract
상기 실시예 2에서 제조된 본 발명의 명일엽박 추출물의 체중 감소 효과를 확인하기 위하여, 고지방 식이로 비만을 유도한 마우스 모델을 선정하여 실험을 수행하였다(J Korean Soc Food Sci Nutr .39(10), 1439-1445(2010)). In order to confirm the weight loss effect of the extract of Myeongil foliar extract of the present invention prepared in Example 2, an experiment was performed by selecting a mouse model inducing obesity with a high fat diet (J Korean Soc Food Sci Nutr .39 (10) , 1439-1445 (2010).
5주령된 C57BL/6 마우스를 1주일간 적응시키고 비만을 유도하기 위해 고지방 식이를 8주간 공급하여 비만을 유도시킨 다음, 각각 8마리씩 총 4군으로 임의적으로 나누어 실험에 이용하였다. 실험군 분류는 하기와 같이 총 4개 군으로 나누어 진행하였으며 투여는 경구투여로 1회 1일 실시하였으며, 명일엽 착즙액, 명일엽박 추출물 모두 각각 0.3g/60kg이 되도록 실험동물 체중 대비 환산하여 투여하였다. 실험군 1 (정상식이 급여군, 이하 도면 Normal로 표시), 실험군 2(고지방 식이 급여 대조군, 이하 도면 Control로 표시), 실험군 3 (고지방 식이 및 명일엽 착즙액 투여군), 실험군 4(고지방 식이 및 명일엽 추출분말 투여군)으로 분류하여 실험하였다. 총 8주간 각 개체의 무게를 1주일 마다 측정하였다.Five-week-old C57BL / 6 mice were acclimated for one week and fed with a high-fat diet for eight weeks to induce obesity to induce obesity, and eight mice each were randomly divided into four groups and used in the experiment. The experimental group was divided into four groups as follows, and administration was performed once a day by oral administration, and the extracts of the extract of Myeongil-day juice and Myeongil-dayak were each administered 0.3g / 60kg in terms of body weight. Experimental Group 1 (normal diet, group shown below as normal), Experimental Group 2 (high fat dietary control, as shown below Control), Experimental Group 3 (high-fat diet and daily juice extract group), Experimental group 4 (high-fat diet and sunday extract) Powder group) to test. Each subject was weighed every week for a total of eight weeks.
그 결과, 도 1에서 보듯이, 시료투여 8주 후에 측정한 고지방 식이 대조군은 초기무게 대비 약 77.8%의 체중증가율을 나타내었으며, 명일엽 착즙액은 67.8%의 체중 증가율을 나타냈다. 이에 비해 명일엽 추출분말은 45.7%의 증가율을 나타냄으로써, 대조군과 비교하였을 때 체중 증가율이 유의적으로 낮게 나타났다(*p<0.05). 명일엽 착즙액 투여군과 명일엽 추출분말 투여군의 체중증가율을 비교하였을 때, 명일엽 추출분말 투여군에서 약 14%의 상대적으로 낮은 체중 증가율을 나타냈다. 이러한 결과로부터, 명일엽 부산물을 추출, 농축, 정제하여 비수용성 성분을 높인 명일엽박 추출물의 항비만 효과가 보다 우수한 것을 확인할 수 있었다.
As a result, as shown in Figure 1, the high-fat diet control group measured 8 weeks after the sample administration showed a weight gain of about 77.8% compared to the initial weight, the juice extract of the day of the week showed a weight increase rate of 67.8%. Compared to the control group, the extract of Myeongil-yup extract showed a 45.7% increase, and the weight gain rate was significantly lower than that of the control group (* p <0.05). When comparing the weight gain rates of the extracts of the extract of the extract of the extract of the extract from the extract of the extract of the extract of the extract from the extract of the extract of the extract of the extract of the extract from the extract of the extract of the extract of the extract of the extract from the extract of the extract, the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract from the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract containing the extract of the extract prepared with the extract of the extract, the extract of the extract of the extract of the extract of the extract, From these results, it was confirmed that the anti-obesity effect of the extract of Myeongil foliar extract that increased the water-insoluble component by extracting, concentrating, and purifying the byproduct of Myeonil.
<< 실험예Experimental Example 2> 2>
명일엽박Leaf leaf
추출물의 체지방 감소 효과 Body Fat Reduction Effect of Extracts
상기 실험예 1의 고지방 식이로 유도된 비만마우스를 대상으로 8주간의 투여가 종료된 후 12시간 이상 절식시키고 나서 희생시켰다. 희생된 마우스의 복부를 절개한 다음, 부고환지방을 적출하였고, 이를 생리식염수로 씻어 수분을 제거한 후 무게를 측정하였다.
Obesity mice induced by the high fat diet of Experimental Example 1 were sacrificed after fasting for at least 12 hours after the end of 8 weeks of administration. The abdomen of the sacrificed mice was incised, and then the epididymal fats were extracted and washed with physiological saline to remove water and weighed.
그 결과, 도 2에서 보듯이, 고지방 식이 급여에 따라 부고환 지방의 무게가 정상군 대비 약 4배 이상 증가한 것을 알 수 있으며, 명일엽 착즙액 투여군은 대조군 대비 약 17.4% 감소시킨 것으로 나타났다. 상대적으로 명일엽 추출분말 투여군은 약 31.4%의 유의적인 감소율을(*p<0.05) 보임으로써 명일엽 추출분말의 부고환 지방 축적 억제 효과가 착즙액 대비 약 2배 이상 높은 것을 확인할 수 있었다. 이러한 결과로부터 본 발명의 명일엽 부산물을 이용한 비수용성 성분이 농축된 명일엽박 추출물의 경우, 명일엽 착즙액 대비 체지방 감소 효과가 증대된 것을 확인하였다.
As a result, as shown in Figure 2, it can be seen that the weight of the epididymal fat increased by more than four times compared to the normal group according to the high-fat diet, the day juice extract group was reduced by about 17.4% compared to the control group. In comparison, the extracts of the extract of Myeongil Lobe extract showed a significant decrease rate of about 31.4% (* p <0.05), indicating that the epididymal fat accumulation inhibitory effect of the extract of Myeongil Lobe extract was about 2 times higher than that of juice. From these results, it was confirmed that the extract of Myeongil foliar extract, in which the water-insoluble component of the present invention, was concentrated, compared to the extract of Myeongil berry juice.
<< 실험예Experimental Example 3> 3>
명일엽박Leaf leaf
추출물의 지방 세포 크기 변화 Changes in Fat Cell Size of Extracts
상기 실험예 1의 고지방 식이로 유도된 비만마우스를 대상으로 8주간의 투여가 종료된 후 12시간 이상 절식시키고 나서 희생시켰다. 마우스의 복부를 절개한 다음, 신속하게 피하지방을 적출하여 4% 포름알데히드(formaldehyde) 용액에 담가 고정하였다. 고정한 다음 수세와 탈수과정을 거친 후 파라핀(paraffin) 용액으로 처리하여 파라핀 블락(paraffin block)을 만들고 4μm두께로 박절하여 헤마토시린(hematoxylin)과 에오신(eosin)으로 염색한 뒤 광학현미경으로 관찰하였다.
Obesity mice induced by the high fat diet of Experimental Example 1 were sacrificed after fasting for at least 12 hours after the end of 8 weeks of administration. The abdomen of the mouse was excised and subcutaneous fat was quickly removed and soaked in 4% formaldehyde solution. After fixation and washing with water and dehydration, the solution was treated with a paraffin solution to form a paraffin block, cut into 4μm thicknesses, stained with hematoxylin and eosin, and observed under an optical microscope. .
그 결과, 도 3에서 보듯이, 명일엽 추출분말 투여군의 지방조직이 명일엽 착즙액과 비교하였을 때 보다 크게 감소하는 것을 확인하였다. 따라서 명일엽 추출분말의 지방세포 크기 감량 효과가 명일엽 착즙액과 비교하였을 때 보다 우수한 것을 확인할 수 있었다.
As a result, as shown in Figure 3, it was confirmed that the adipose tissue of the extract of Myeongil lobe extract powder was significantly reduced compared to the extract of Myungil lobe juice. Therefore, it was confirmed that the fat cell size reduction effect of the extract of Myeongil Leaf was superior to that of Myungil Leaf juice.
본 발명의 명일엽박 추출물은 원물인 명일엽의 착즙액에 비해서도 우수한 체중감소, 체지방 감소 및 지방세포의 크기 감소 효과를 가진다. 따라서, 본 발명의 명일엽박 추출물은 비만 예방 및 치료의 목적으로 유용하게 이용될 수 있다.
Myeongil leaf extract of the present invention has an excellent weight loss, body fat reduction and fat cell size reduction effect compared to the juice of the original Myeongil leaf. Therefore, Myeongil leaf extract of the present invention can be usefully used for the purpose of preventing and treating obesity.
Claims (6)
Food composition for the prevention and treatment of obesity, including the extract of Mt.
The composition of claim 1, wherein the extract of Myeongil Foil is a non-aqueous fraction of the organic solvent extract of Myeongil Foil.
(a) 명일엽 박의 유기용매 추출물을 제조하는 단계; 및
(b) 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계를 포함하는 방법에 의해 제조된 것임을 특징으로 하는 조성물.
The extract of claim 1, wherein
(a) preparing an organic solvent extract of perilla leaf gourd; And
(b) a composition prepared by the method comprising the step of removing water-soluble components by adding water to the extract of step (a).
(a) 명일엽 박의 유기용매 추출물을 제조하는 단계;
(b) 상기 (a) 단계의 추출물에 물을 첨가하여 수용성 성분을 제거하는 단계; 및
(c) 상기 (b) 단계의 수용성 성분이 제거된 추출물을 탄소수 1 내지 6의 알코올을 첨가하여 알코올 용해 분획을 수득하는 단계를 포함하는 방법에 의해 제조된 것임을 특징으로 하는 조성물.
The extract of claim 1, wherein
(a) preparing an organic solvent extract of perilla leaf gourd;
(b) removing water-soluble components by adding water to the extract of step (a); And
(c) a composition comprising the step of obtaining an alcohol soluble fraction by adding an alcohol having 1 to 6 carbon atoms to the extract from which the water-soluble component of step (b) is removed.
The solvent according to any one of claims 2 to 4, wherein the organic solvent is one selected from the group consisting of alcohols having 1 to 6 carbon atoms, acetone, ethyl acetate, n-nucleic acid, diethyl ether, acetone and benzene. The composition characterized in that the.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110040964A KR101344676B1 (en) | 2011-04-29 | 2011-04-29 | Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110040964A KR101344676B1 (en) | 2011-04-29 | 2011-04-29 | Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120122664A true KR20120122664A (en) | 2012-11-07 |
KR101344676B1 KR101344676B1 (en) | 2013-12-23 |
Family
ID=47508890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110040964A KR101344676B1 (en) | 2011-04-29 | 2011-04-29 | Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101344676B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900006858A1 (en) * | 2019-05-15 | 2020-11-15 | Abresearch Srl | Preparation of insoluble polysaccharides obtained from suspended plant cell cultures for the treatment of Clostridium difficile infections |
CN113925167A (en) * | 2021-10-14 | 2022-01-14 | 青岛大学 | Ultrahigh-pressure non-concentrated Angelica keiskei returning raw juice and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009073761A (en) * | 2007-09-20 | 2009-04-09 | Nippon Seibutsu Kagaku Kenkyusho:Kk | Leptin production promoter |
-
2011
- 2011-04-29 KR KR1020110040964A patent/KR101344676B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900006858A1 (en) * | 2019-05-15 | 2020-11-15 | Abresearch Srl | Preparation of insoluble polysaccharides obtained from suspended plant cell cultures for the treatment of Clostridium difficile infections |
WO2020230080A1 (en) * | 2019-05-15 | 2020-11-19 | Abresearch Srl | Preparation of insoluble polysaccharides obtained from plant cell cultures in suspension for the treatment of clostridium difficile infections |
CN113925167A (en) * | 2021-10-14 | 2022-01-14 | 青岛大学 | Ultrahigh-pressure non-concentrated Angelica keiskei returning raw juice and preparation method thereof |
CN113925167B (en) * | 2021-10-14 | 2024-03-22 | 青岛大学 | Ultrahigh-pressure non-concentrated return juice of angelica keiskei and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101344676B1 (en) | 2013-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101676751B1 (en) | Method for manufacturing extract of citrus preicarp and composition for preventing, improving or treating liver injury | |
KR101363111B1 (en) | Pharmaceutical composition containing paddy husk and barley husk extract as activeingredient | |
US11622984B2 (en) | Composition comprising aster sphathulifolius maxim extract for preventing, improving, or treating muscular diseases or for improving muscular functions | |
WO2007102439A1 (en) | Fractionation product of aqueous extract of eucommia ulmoides oliver leaf, and composition for oral ingestion comprising the fractionation product | |
JP5088846B2 (en) | A fraction of Tochu Nakaha extract and an anti-obesity agent containing the fraction | |
KR101675064B1 (en) | A composition comprising the complex extract for enhancing power of exercise performance and promoting physical stamina | |
KR101344676B1 (en) | Composition for preventing and treating obesity comprising Angelica Keiskei Koid. extract | |
JP6524222B2 (en) | Composition for improving muscle function or exercise capacity comprising kilenol or extract of Sieges vecchia herb | |
KR101698201B1 (en) | Composition for increasing muscle mass, anti-fatigue and enhancing exercise performance comprising panduratin derivatives or Boesenbergia pandurata extract | |
KR20190135438A (en) | Antioxidant composition comprising mixture of the extract of Chunggukjang and Modordica charantia | |
KR101135132B1 (en) | Novel use of panduratin derivatives or extract of Boesenbergia pandurata | |
KR101731152B1 (en) | Anti-diabetic composition containing the extract of actinidia arguta leaves or fractions thereof | |
KR101321203B1 (en) | Anti-diabetic composition comprising Angelica Keiskei Koid. extracts | |
JP4537024B2 (en) | Inflammatory disease preventive / therapeutic agent | |
KR102248059B1 (en) | Composition for anti-inflammatory or whitening comprising green barley extract or its fractions and uses thereof | |
KR20220067467A (en) | A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage | |
KR102217264B1 (en) | Composition for Preventing, Improving or Treating of muscular disease containing Codium SPP. algae extract | |
KR101854180B1 (en) | Health function food for preventing or improving liver injury comprising extract of citrus preicarp | |
CN110679818A (en) | Multifunctional shepherd's purse water extract solid beverage and preparation method thereof | |
KR20050097698A (en) | A method for producing oleanolic acid and ursolic acid from persimmon peel | |
KR102144526B1 (en) | Composition for reducing body fat comprising xanthorrhizol or Java tumeric extract | |
KR100539457B1 (en) | Composition For Preventing And Treating Hyperlipidemia, Arteriosclerosis And Fatty Liver Comprising The Extract Of Sophorae Fructus | |
KR101491492B1 (en) | Extraction method of Citrus hassaku pericarp for increasing anti-inflammation activity | |
KR20230058291A (en) | Novel Method for Preparing Immature Sword Bean Pod Extracts Having Increased Rutin Content and Functionality, and Immature Sword Bean Pod Extracts Prepared Thereby | |
TW202228754A (en) | Composition for enhancing exercise capacity and recovery from fatigue containing fermented and aged noni, coconut sugar or muscovado sugar as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20161007 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20171019 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20181010 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20191022 Year of fee payment: 7 |